☆ 4.3 Letter

Should anti-CD20 be used as an immune reconstitution therapy?

MULTIPLE SCLEROSIS JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

COVID-19 Vaccine Response in People with Multiple Sclerosis

Emma C. Tallantyre et al.

Summary: The study found that some disease modifying therapies are associated with attenuated serological responses to SARS-CoV-2 vaccination in people with multiple sclerosis, including anti-CD20 monoclonal antibodies and fingolimod treatment. Additionally, vaccine type and treatment duration also impact vaccine response.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Editorial Material Clinical Neurology

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO

Zoe L. E. van Kempen et al.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Editorial Material Clinical Neurology

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Yes

Leoni Rolfes et al.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Steve Simpson-Yap et al.

Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.

NEUROLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Efficacy classification of modern therapies in multiple sclerosis

Imtiaz A. Samjoo et al.

Summary: According to the ABN guidelines, cladribine and ofatumumab are classified as high efficacy treatments, while ocrelizumab and ozanimod (1.0 mg) are classified as moderate or high efficacy depending on the approach used.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases

Alexandre Avouac et al.

Summary: Rituximab used as maintenance therapy in CNS inflammatory diseases is frequently associated with reduced IgG levels and increases the infection risk of the most vulnerable patients.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Livnat Brill et al.

Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna et al.

JAMA NEUROLOGY (2020)

Add to Collection

Review Immunology

Immunological consequences of immune reconstitution therapy in multiple sclerosis: A systematic review

Johann Sellner et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Article Clinical Neurology

P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions

T. Derfuss et al.

CLINICAL NEUROPHYSIOLOGY (2020)

Add to Collection

Article Clinical Neurology

Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension

Stephen L. Hauser et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

David Baker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Clinical Neurology

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

David Baker et al.

JAMA NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Both cladribine and alemtuzumab may effect MS via B-cell depletion

David Baker et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection

Article Medicine, General & Internal

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey A. Cohen et al.

LANCET (2012)

Add to Collection

Article Medicine, General & Internal

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair J. Coles et al.

LANCET (2012)

Add to Collection

Article Rheumatology

Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial

Clifton O. Bingham et al.

ARTHRITIS AND RHEUMATISM (2010)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Gavin Giovannoni et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Clinical Neurology

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or et al.

ANNALS OF NEUROLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.